All In Biotech

Drug Trial Radar · NCT06581328

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

A Phase 4 Study Evaluating Moderate to Severely Active Ulcerative Colitis or Crohn's Disease and the Use of Vedolizumab Subcutaneous Within a Community Setting

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

May 1, 2027

Study completion Jun 1, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab. During the study, participants will visit their study clinic several times.

Conditions

  • Ulcerative Colitis
  • Crohn's Disease

Interventions

  • Vedolizumab IVDrug

    Vedolizumab IV infusion

  • Vedolizumab SCDrug

    Vedolizumab SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of CD Participants With 2-item Patient-reported Outcome Measure (PRO-2) Remission at Week 14Time frame: At Week 14
  2. Percentage of UC Participants With PRO-2 Remission at Week 14Time frame: At Week 14

Locations

101 sites in 1 country. Site status is shown where the registry gives one.

  • Gastro Health

    Birmingham, Alabama · Recruiting

  • East View Medical Research

    Mobile, Alabama · Recruiting

  • AZ Gastro Care

    Chandler, Arizona · Recruiting

  • Spectrum Research Institute LLC

    Gilbert, Arizona · Recruiting

  • GI Alliance- Sun City

    Sun City, Arizona · Recruiting

  • UAMS Health Gastroenterology Clinic

    Little Rock, Arkansas · Withdrawn

  • Gastroenterology and Liver Institute

    Escondido, California · Recruiting

  • Inland Empire Gastroenterology

    Murrieta, California · Withdrawn

  • United Clinical Research Institute

    Murrieta, California · Recruiting

  • Digestive Health Institute

    Newport Beach, California · Withdrawn

  • Knowledge Research Center

    Orange, California · Withdrawn

  • Medical Associates Research Group, Inc.

    San Diego, California · Withdrawn

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado · Recruiting

  • Rocky Mountain Endocopy Centers LLC

    Littleton, Colorado · Recruiting

  • Access Research Institute

    Brooksville, Florida · Recruiting

  • Gastro Florida

    Clearwater, Florida · Recruiting

  • Doral Medical Research, LLC

    Hialeah, Florida · Withdrawn

  • Digestive and Liver Center of Florida, P.A.

    Kissimmee, Florida · Recruiting

  • Gastro Health Research - Miami

    Miami, Florida · Recruiting

  • Endoscopic Research, Inc.

    Orlando, Florida · Recruiting

  • Orlando Health-Orlando Regional Medical Center

    Orlando, Florida · Recruiting

  • Digestive and Liver Center of Florida

    Orlando, Florida · Withdrawn

  • Gastro Health Research - Pensacola

    Pensacola, Florida · Recruiting

  • West Central Gastroenterology d/b/a Gastro Florida

    Pinellas Park, Florida · Recruiting

  • Digestive Healthcare of Georgia

    Atlanta, Georgia · Recruiting

  • AGA GA Research LLC

    Atlanta, Georgia · Recruiting

  • Atlanta Center for Gastroenterology, P.C.

    Decatur, Georgia · Withdrawn

  • Yapp, Rockford M.D. (Private Practice)

    Downers Grove, Illinois · Recruiting

  • GI Alliance - Glenview

    Glenview, Illinois · Recruiting

  • Avicenna Clinical Research - Gastroenterology and Internal Medicine Specialists

    Lake Barrington, Illinois · Recruiting

  • Suburban Gastroenterology

    Naperville, Illinois · Withdrawn

  • GI Partners of Illinois - Southwest Gastroenterology

    Oak Lawn, Illinois · Recruiting

  • Rockford Gastroenterology Associates, Ltd.

    Rockford, Illinois · Recruiting

  • Springfield Clinic

    Springfield, Illinois · Recruiting

  • Riverview Health

    Westfield, Indiana · Recruiting

  • Hutchinson Clinic

    Hutchinson, Kansas · Recruiting

  • Tri-State Gastroenterology Associates

    Crestview Hills, Kentucky · Recruiting

  • Baton Rouge General Medical Center - Bluebonnet Campus

    Baton Rouge, Louisiana · Recruiting

  • Combined Gastro LLC

    Lafayette, Louisiana · Recruiting

  • GI Alliance

    Metairie, Louisiana · Recruiting

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.